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Measurement of serum irisin in the different  
stages of chronic kidney disease 
 
 
 
Abstract 
Background: Irisin is a myokine that regulates energy metabolism by inducing browning 
of adipose tissue. The aim of this study was to evaluate the relationship between irisin level and 
biochemical parameters of chronic kidney disease (CKD) patients in stage 2 and stage 4. 
Methods: The research was a cross-sectional study; the study population included patients 
with CKD who were over 18 years of age, included 90 individuals with CKD, of these 
participants, 45 were in the second stage of the CKD while the other 45 subjects were in 
the fourth stage. Serum irisin concentration plus the level of glucose (Glu), urea, creatinine 
(Cr) and hemoglobin (Hb) were measured. 
Results: In the present study, the serum irisin level of patients in stage 4 was significantly 
reduced (13.00 ng / ml) compared with patients in stage 2(21.41 ng / ml). 
Conclusion: With the progression of CKD from stage 2 to stage 4, parameters such as 
serum Cr, TG, LDL, FBS, BUN and urea levels significantly increased. Inversely, factors 
such as irisin, GFR, Alb, HDL and Hb levels significantly decreased. These findings 
suggest that irisin may be involved in the regulation of biochemical factor levels in CKD 
patients through the progression from stage 2 to stage 4. 
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Last stage of chronic kidney disease (CKD) is known as the end stage of renal 
disease (1). At this stage, kidney function damage was almost irreversible, and for the 
prevention of uremia, the patient undergoes dialysis or kidney transplantation(2, 3).Several 
factors contribute to the development of this disease, including hypertension, obesity, 
diabetes and cardiovascular disease(4). CKD as a syndrome can cause some of these 
disease including cardiovascular disease (CVD), hypertension and anemia (9). Several 
studies have been done to classify chronic kidney disease, and this classification is done 
when the disease has been created for three months or more based on the rate of 
glomerular filtration, estimated GFR (eGFR): more than 90 mL/min per 1·73 m² (stage 1 
normal or high), 60–89 mL/min per 1·73 m² (stage 2 mildly decreased), 45–59 mL/min per 
1·73 m² (stage 3 a mildly to moderately decreased), 30–44 mL/min per 1·73 m² (stage 3b 
moderately to severely decreased), 15–29 mL/min per 1·73 m² (stage 4 severely 
decreased), and less than 15 mL/min per 1·73 m² (stage 5 kidney failure), when GFR is 
less than 15 mL/min per 1·73 m² (stage 5), in this stage, the person reaches the end stage 
kidney disease (ESKD) (6). In this condition, the kidney is unable to maintain the normal 
homeostasis of the body (5-7).  
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The prevalence of CKD in the world is between 7-12%, 
biochemical factors change with the onset of CKD, some 
factors, such as Alb, are a reflection of the progression of the 
disease, and the amount of Alb in urine output is directly 
related to the progression of the disease, on the other hand, 
factors such as proteinuria, hypertension, hyperuricemia 
contribute to CKD stability (8-10). Irisin is a myokine that 
consists of 112 amino acids and is produced by skeletal 
muscle tissue, peroxisome proliferator-activated receptorα 
(PPARα) coactivator 1α(PGC-1α)which is also induced by 
exercise, stimulate the expression of fibronectin type III 
domain containing (FNDC5) membrane section, which is 
further liberated by proteolytic cleavage into the blood 
stream, this released part is called irisin (11, 12). Studies 
have argued that irisin levels change in people with chronic 
renal disease, and this reduction of irisin has a reverse 
relationship with serum urea and creatinine levels. Also, 
changes in the irisin level have a clear effect on lipid 
profiles, while reduction in irisin levels leads to reduced 
HDL level, furthermore, irisin can be used as therapeutic 
agent to treat cardiovascular disease(13, 14). Decreasing 
irisin serum concentration simultaneously with the 
increasing CKD stage can predict kidney function (15). 
Therefore, the aim of this study was to evaluate the 
relationship between irisin level and biochemical parameters 
of CKD patients, stage 2(early CKD) and stage 4 (stage 
before ESKD) and its association with CKD progression.  
 
 
Methods  
The present study is a cross-sectional study of which its 
population included patients with CKD who were above 18 
years of age, including 90 individuals with CKD. Of these 
participants, 45 were in the second stage of CKD while the 
other 45 were in the fourth stage. The study included 20 
women and 25 men in the second stage of CKD (10 were 
diabetic patients) as well as 28 women and 17 men in stage 4 
CKD (16 were diabetics).With regard to the patient's age, 
creatinine and gender of the patient, the MDRD equation 
was used to determine stage 2 (GFR=90-60) and 4(GFR=30-
15). Exclusion criteria were as follows: patients with 
malignancy, acute inflammation, polycystic kidney disease, 
acute infection, as well as pregnant women. 10 ml blood 
sample was collected from each patient participant in fasting 
condition. After that, serum centrifugation and biochemical 
tests were performed. This study was carried out at the 
Kidney Transplantation Center, Shaheed Behshti Hospital, 
Faculty of Medicine, Babol University of Medical Sciences, 
Babol, Iran from September 2016 to March 2018. All 
subjects in the research study provided signed informed 
consent of the experimental protocol recommended by the 
our university ethics committee, and in agreement with the 
Helsinki Declaration. The Ethics Committee of Babol 
University approved the study (MUBABOL.REC.1395.215). 
Laboratory measurement: Serum irisin concentration was 
measured via the enzyme-linked immunosorbent assay 
(ELISA) kit (Zell BioGmbH, Germany, ZB-13253S-H9648), 
the intra-assay coefficient of variability (CVs) and inter-
assay (CVs) reported by the manufacturer were CV<10% 
and CV<12%, respectively. The sensitivity of the assay was 
0.09 ng/ml and the assay range of kit was 2 ng/ml - 
64 ng/ml. Furthermore, in this research study, the amount of 
biochemical parameters such as triglyceride (TG), total 
cholesterol (Chol), HDL, LDL and Glu (precision of 
measurement at mg / dl) and Alb (precision of measurement 
at g / dl) in serum was measured by standard biochemical 
methods as previously described with some modifications 
(32-38). The amount of Hb was measured by cyan hematin 
method. 
Statistical methods and analysis: Continuous variables for 
normal distribution were tested using Kolmogorov–Smirnov 
test, Student’s t-test was used to analyze the data with 
normal distribution (expressed as mean ± SD), for non-
normal distribution, Mann-Whitney was used (expressed as 
median (Q3-Q1), for the evaluation of the correlation between 
irisin level and parametric continuous variables, Pearson’s 
correlation coefficient was used, and for nonparametric 
variables, Spearman’s correlation was used. All reported p-
values were 2-sided, and a p-value of <0.05 was considered 
statistically significant. Statistical analysis was performed 
with SPSS software Version 25; in addition, the ROC 
statistical test was performed to determine the diagnostic 
accuracy of irisin, Alb and hemoglobin (Hb) as the 
biochemical markers to differentiate between stage 2 and 
stage 4 patients with CKD. The area under the curve, cut-off 
point, sensitivity and specificity of each biochemical factor 
was calculated. 
 
 
Results 
The demographic characteristics of patients were shown 
in table 1. The data of table 2 shows that the serum level of 
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irisin (median) in patients in stage 2 was 21.41 ng / ml and 
for stage 4 was 13.00 ng / ml, based on Mann Whitney's 
statistical test. Irisin in patients with CKD in stage 4 showed 
a significant decrease in comparison to stage 2(p <0.001). As 
shown in table 2, median of  creatinine (Cr), low density 
lipoprotein cholesterol (LDL), FBS,TG and also means of 
Chol increase from stage 2 to stage 4 of CKD.  
 
Table 1. The demographic characteristics of patients. 
Variable Stage 2 Stage 4 
Male 25 17 
Female 20 28 
Hypertension 11 14 
Diabetic 6 20 
Smoking 9 11 
Diuretics 8 13 
Β blockers 10 15 
Calcium-channel blockers 16 18 
ACE inhibitors/ARBs 13 16 
 
On the other hand, the median of glomerular filtration 
rate (GFR), albumin, the mean of HDL and Hb level 
decrease with the increasing stage of disease. The mean of 
normal indices as (mean ± standard deviation) as well as the 
abnormal indicators as median (Q3-Q1) was shown in table 
2. The Mann-Whitney test for abnormal data between two 
groups of CKD patients in stage 2 and stage 4 of this study 
showed that Cr ،GFR ،Alb, TG and FBS is a significant 
difference between the two groups. The Pearson correlation 
test was used to determine the relationship between serum 
irisin and biochemical factors separately at stage 2 and stage 
4. In stage 2, these patients had a negative correlation 
between Cr, age, FBS, BUN, LDL, Chol, urea with serum 
irisin. On the other hand, GFR, TG, Hb and ALb had 
positive correlation with serum irisin (P>0.05), and among 
these parameters in stage2, factors like BUN=(r=-0.309 
P=0.039)، UA=(r=-0.324 P=0.030) and Alb=(r=0.334 
P=0.025) have a meaningful relationship. In stage 4, factors 
Cr, age, HDL, BUN, LDL, Chol and UA had a negative 
correlation with serum irisin level. But  GFR, FBS, TG, Hb 
and ALb factors had positive correlation with serum irisin, 
and among these parameters in stage 4, factors like Cr =(r=-
0.380  P=0.010)  ،GFR=(r=0.413  P=0.005) and Hb 
=(r=0.408 P=0.005) have a meaningful relationship (table 3). 
 
Table 2: Mean of normal indices as (mean±SD) as well as 
abnormal indicators as median (Q3-Q1). 
Variable Stage 2 Stage 4 P-value 
Age 45.02±14.46 63.83±14.44 P<0.001 
Urea ( mg/dl) 6.55±1.08 8.18±1.68 P<0.001 
BUN( mg/dl) 37.38±3.57 41.31±6.53 P<0.001 
Hb( g/l) 13.41±1.62 11.4±1.3 P<0.001 
Chol ( mg/dl) 171.7±43.6 180.6±47.1 P>0.05 
HDL( mg/dl) 46.17±10.43 41.85±9.87 P<0.05 
Variable Median( Q3-Q1) Median(Q3-Q1) P-value 
Irisin(ng/ml) 21.41(8.49) 13.00(6.69) P<0.001 
Cr( mg/dl) 1.1(0.20) 2.6(0.64) P<0.001 
GFR 65.95(10.91) 22.35(8.1) P<0.001 
TG( mg/dl) 117.1(67) 160(93.5) P<0.01 
LDL( mg/dl) 89(64.50) 100(48.5) P<0.01 
Alb( g/dl) 3.8(0.87) 3.2(0.55) P<0.001 
FBS( mg/dl) 101(27.50) 121(47.5) P<0.01 
Alb, Albumin ;Cr, creatinine; GFR, glomerular filtration rate; FBS, fasting 
blood glucose; TG ,triglyceride; Chol, cholesterol; UA ,uric acid; BUN, 
blood urine nitrogen; HDL, high density cholesterol; LDL, low density 
cholesterol ,Hb, hemoglobin. 
 
Table 3:  Correlation between Irisin level and other variables in stages 2 and 4. 
Stage2/var
iables 
Alb Cr GFR FBS TG Chol UA BUN HDL LDL Hb 
Irisin r=-0.334 
p=0.025 
r=-0.142 
P=0.353 
r=0.051 
p=0.741 
r=-0.147 
P=0.335 
r=0.108 
P=0.481 
r=-0.022 
P=0.888 
r=0.324 
P=0.030 
r=-0.309 
P=0.039 
r=0.171 
P=0.260 
r=-0.086 
P=0.575 
r=0.238 
P=0.115 
Stage 
4/variables 
r=0.174 
P=0.253 
r=-0.380 
P=0.010 
r=0.413 
P=0.005 
r=0.026 
P=0.863 
r=0.234 
P=0.122 
r=-0.001 
P=0.994 
r=-0.128 
P=0.332 
r=-0.202 
P=0.182 
r=-0.241 
P=0.111 
r=-0.093 
P=0.543 
r=0.408 
P=0.005 
Alb, Albumin ;Cr, creatinine; GFR, glomerular filtration rate; FBS, fasting blood glucose; TG ,triglyceride; Chol, cholesterol;, UA uric acid; BUN, blood urine 
nitrogen; HDL, high density cholesterol; LDL, low density cholesterol, Hb, hemoglobin. 
 
The analysis of ROC curves (figure 1) indicated that the 
sensitivity and specificity in the diagnosis of composite  
 
endpoint events for irisin, Alb and Hb were 80, 73% and 80, 
85% and also 71, 73%, respectively. Moreover, area under 
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the curve for irisin, Alb and Hb were 0.80, 0.81, 0.89. ROC  
curve to evaluate the sensitivity and specificity of irisin, Alb, 
Hb levels between stage 2 and stage 4 was shown in figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: ROC curve to evaluate the sensitivity and 
specificity of irisin, Alb, Hb between stage 2 and stage 4 
 
Discussion 
In the present study, the serum irisin level of patients in 
stage 4 was significantly reduced compared with stage 2 
patients, this finding is consistent with most studies that 
suggest that the amount of irisin is decreased in the serum of 
CKD patients (15, 21). One possible mechanism of the this 
reduction of irisin level might be due to muscle volume, 
because  patients may have lower muscle volume in stage 4 
in comparison to stage 2 . Irisin is produced within muscle, 
and total muscle volume can affect the irisin level. On the 
other hand, inflammation, oxidative stress, activation of 
advanced protein glycation routes, may be the causes of 
irisin reduction in patients with CKD (30, 31). 
Moreover,  study point to the fact that the reduction of 
irisin in subjects  with CKD plays a very important role in 
diabetes (22). With the progression of CKD from stage 2 to 
stage 4, parameters such as serum Cr, TG, LDL, FBS, BUN 
and urea levels significantly increased. Inversely, factors 
such as GFR, Alb, HDL and Hb levels showed a significant 
reduction. These findings suggest that irisin may be involved 
in the regulation of biochemical factor levels in CKD 
patients.  
Pearson correlation analysis showed that serum irisin 
level in stage 2 is inversely correlated to BUN, urea levels 
and on the contrary irisin has direct correlation with Alb 
level. In stage 4, irisin is inversely associated with Cr level 
and directly correlated with GFR and Hb levels (24). It is 
also demonstrated that irisin is dependent on Hb level (13, 
23-25). The results of our study are in line with the study of 
Ming-Shien Wen et al. on CKD patients. We observed in 
CKD patients that the BUN levels in stage 2 and Cr in stage 
4 inversely correlated with irisin. In another study, 
researchers reported that with increasing irisin, HDL did not 
change significantly (26).  
We observed a direct correlation between serum irisin 
level and GFR level in stage 4 CKD patients. Irisin level 
decreased and was directly correlated to GFR in the 
advanced CKD group, and these findings confirm the results 
of our study (20, 26). In a systematic review and meta-
analysis study, it has been shown that increased serum urea 
level caused increased risk of CKD progression, and urea 
level can be considered as a factor associated with the 
disease (27). In the present study, irisin had an indirect 
correlation with urea level in CKD stage 2. Subsequently, 
with the progression of CKD from stage 2 to stage 4, the 
amount of irisin decreased while the urea increased. This 
shows that irisin can be affected by urea level, however, 
more studies are needed in this issue. Another study has 
shown that there is albuminuria in CKD patients and 
increasing irisin significantly reduces the risk of CKD. We 
found that in stage 4, patients had lower serum Alb levels 
than stage 2, and serum Alb was directly correlated to irisin 
level in stage 2 (26, 28). Reducing Alb level in patients with 
CKD was reported (29). In the present study, the ROC curve 
showed that irisin has the specificity and sensitivity to 
differentiate between stage 2 and stage 4 in CKD. 
Our study has some limitations. First, a major limitation 
of the study is that the concentration of other compounds 
was not measured in serum. This fact does not allow us to 
derive conclusions about other compound changes in relation 
progression of CKD from stage 2 to stage 4. The second 
limitation of our study was that present study did not allow 
us to infer the mechanism of action of irisin in CKD. The 
power of the present study is that we assessed the 
biochemical factors levels in CKD patients through the 
progression from stage 2 to stage 4 for first time. 
In conclusion, the present findings suggest that irisin may 
be involved in the regulation of biochemical factors levels. 
Moreover, irisin may play a major role in affecting 
biochemical factors levels in CKD patients.  Lower levels of 
irisin in stage 4 in comparison to stage 2 are associated with 
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lower HDL cholesterol, GFR, Hb and Alb levels. The 
mechanism underlying the decrease in irisin in CKD is 
unknown. Further basic study is needed to clarify the 
mechanisms underlying the effects of irisin in CKD. 
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